Hemostemix (CVE:HEM) Reaches New 12-Month Low – Here’s What Happened

Hemostemix Inc. (CVE:HEM) reached a new 52-week low on Thursday . The stock traded as low as C$0.08 and last traded at C$0.09, with a volume of 12750 shares trading hands. The stock had previously closed at C$0.09.

Hemostemix Stock Up 5.9%

The company has a market cap of C$16.96 million, a P/E ratio of -3.33 and a beta of 0.80. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The company has a fifty day moving average of C$0.09 and a 200 day moving average of C$0.09.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.